Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07284892 in Advanced Solid Tumors
NCT04800822Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Mar 2021
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of PF-07284892 in solid tumor, non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) (9 arms), sponsored by Pfizer. Primary endpoints: Dose Limiting Toxicities at 21 days, Treatment-Emergent Adverse Events and 3 more. Started Mar 2021; status: terminated.
02
Drugs
PF-07284892
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04800822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04800822.